Drug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to yield burgeoning rates of regulatory filings for approval and eventually new advanced medicine alternatives for clinicians and their patients to consider.
In all, respondents in this installment of Scrip Asks for 2024 talked about paradigm shift in cell and gene therapy, manufacturing trends that companies are turning to keep ahead of demand, supply and access issues for health care providers and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
